Attached Carole Ho - 05 Jan 2023 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Signature
/s/ Tyler Nielsen, by power of attorney
Issuer symbol
DNLI
Transactions as of
05 Jan 2023
Net transactions value
-$116,568
Form type
4
Filing time
09 Jan 2023, 20:43:39 UTC
Previous filing
05 Jan 2023
Next filing
10 Jan 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale $74,968 -2,636 -1.4% $28.44 180,364 05 Jan 2023 See footnote F1, F2, F3, F4
transaction DNLI Common Stock Sale $41,600 -1,451 -0.8% $28.67 178,913 06 Jan 2023 See footnote F4, F5
holding DNLI Common Stock 25,000 05 Jan 2023 See footnote F6
holding DNLI Common Stock 131,467 05 Jan 2023 Direct F3, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.
F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $28.17 to $28.68 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 Reflects the issuance of shares to the Rohatgi-Ho Family 2009 Revocable Trust in connection with the vesting of 7,500 RSUs held by the Reporting Person.
F4 The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
F5 The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F6 The shares are held of record by the Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children.
F7 Includes 131,057 RSUs.